The Greater Cannabis Company, Inc. (GCAN)
|Address:15 Walker Avenue
Baltimore, MD 21208
|Phone||443 738 4051|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
The Greater Cannabis Company, Inc., a biopharmaceutical company, focuses on the development and commercialization of technology for transmucosal delivery of legal medical or recreational cannabis and cannabinoids.
The company's initial product is an oral transmucosal patch platform, which provides loaded actives to be absorbed by the buccal mucosa into the body.
It intends to commercialize the technology by sublicensing or partnering with licensed producers, distributors, processors, consumer product, and pharmaceutical companies.
The company was founded in 2014 and is based in Baltimore, Maryland.
|Aitan Zacharin||Chairman, President, Chief Executive Officer, Acting Chief Financial Officer and Treasurer|
|Mark Frederick Radom||Chief Legal Officer, Vice President and General Counsel|
Latest SEC Filings
|Jun 14, 2021||S-1/A||General form for registration of securities under the Securities Act of 1933|
|May 17, 2021||10-Q||Quarterly report [Sections 13 or 15(d)]|
|May 7, 2021||S-1||General form for registration of securities under the Securities Act of 1933|
|Mar 26, 2021||10-K||Annual report [Section 13 and 15(d), not S-K Item 405]|
|Mar 16, 2021||8-K||Current report|
|Nov 19, 2020||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Nov 16, 2020||NT 10-Q||Notification of inability to timely file Form 10-Q or 10-QSB|
|Aug 17, 2020||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Aug 13, 2020||NT 10-Q||Notification of inability to timely file Form 10-Q or 10-QSB|
|Jul 22, 2020||DEF 14C||Other definitive information statements|
|View All SEC filings|